Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Lexicon Pharmaceuticals, Inc. (LXRX)
Price$2.24Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M | $6.0M | $1.1M | $0 | $0 | $23.4M | $32.3M | $26.6M | $15.9M | $0 | $130.0M | $22.9M | $2.2M | $1.1M | $1.8M | $4.9M | $10.7M |
| Gross profit | $49.5M | $5.4M | $1.0M | $0 | $0 | $21.5M | $29.1M | $24.1M | $14.0M | $0 | $130.0M | — | — | — | — | — | — |
| Gross margin | 99.45% | 89.74% | 92.34% | — | — | 91.76% | 90.01% | 90.63% | 88.05% | — | 100.00% | — | — | — | — | — | — |
| Research & development | $61.1M | $84.5M | $58.9M | $52.8M | $55.0M | $153.6M | $91.9M | $100.2M | $152.2M | $164.0M | $95.2M | $89.3M | $89.7M | $82.6M | $91.8M | $78.5M | $81.2M |
| Operating expenses | $98.7M | $202.5M | $173.0M | $100.9M | $87.4M | $204.4M | $180.6M | $166.5M | $222.3M | $206.4M | $128.5M | $123.2M | $104.6M | $109.5M | $115.9M | $100.6M | $100.7M |
| Operating income | −$48.9M | −$197.1M | −$171.8M | −$100.8M | −$87.1M | −$47.8M | $141.4M | −$103.3M | −$130.6M | −$127.2M | $1.5M | −$100.4M | −$102.4M | −$108.4M | −$114.1M | −$95.7M | −$90.0M |
| Operating margin | −98.21% | −3,284.74% | −15,472.97% | — | — | −204.24% | 437.49% | −388.52% | −822.05% | — | 1.13% | −439.16% | −4,607.16% | −9,955.46% | −6,170.63% | −1,950.24% | −840.71% |
| EBITDA | −$48.3M | −$196.6M | −$171.2M | −$100.3M | −$86.8M | −$44.9M | $145.1M | −$99.6M | −$127.2M | −$125.1M | $2.2M | −$98.4M | −$99.5M | −$104.2M | −$109.2M | −$90.3M | −$83.8M |
| EBITDA margin | −96.96% | −3,275.84% | −15,423.06% | — | — | −191.70% | 448.79% | −374.66% | −800.66% | — | 1.69% | −430.73% | −4,478.31% | −9,570.71% | −5,906.33% | −1,840.34% | −783.15% |
| Net income | −$50.3M | −$200.4M | −$177.1M | −$101.9M | −$87.8M | −$58.6M | $130.1M | −$120.5M | −$123.0M | −$131.4M | −$4.7M | −$100.3M | −$104.1M | −$110.2M | −$116.2M | −$101.8M | −$82.8M |
| Net profit margin | −101.08% | −3,339.49% | −15,956.67% | — | — | −250.27% | 402.50% | −453.48% | −774.03% | — | −3.60% | −438.85% | −4,686.14% | −10,120.39% | −6,285.29% | −2,073.66% | −773.64% |
| Basic EPSper basic share | -$0.14 | -$0.63 | -$0.80 | -$0.62 | -$0.60 | -$0.53 | $1.23 | -$1.14 | -$1.17 | -$1.27 | -$0.05 | -$1.31 | -$1.42 | -$0.23 | -$0.34 | -$0.34 | -$0.57 |
| Diluted EPSper diluted share | -$0.14 | -$0.63 | -$0.80 | -$0.62 | -$0.60 | -$0.53 | $1.16 | -$1.14 | -$1.17 | -$1.27 | -$0.05 | -$1.31 | -$1.42 | -$0.23 | -$0.34 | -$0.34 | -$0.57 |
Owners
Reported shareholders
39.20%of listed shares
Artal Group S.A.175.16M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Artal Group S.A. | 39.20%175.16M shares |
Artal Participations S.a r.l. | ≈30.47%136.18M shares |
FMR LLC | 11.59%51.78M shares |
DEBBANE RAYMOND | ≈11.58%51.75M shares |
Siren, L.L.C. | 9.91%44.3M shares |
Sessa Capital IM, L.P. | 4.24%18.96M shares |
BlackRock, Inc. | 3.88%17.35M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.22%9.9M shares |
Point72 Asset Management, L.P. | 1.85%8.25M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.40%6.24M shares |
STATE STREET CORP | 1.10%4.92M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.53%2.36M shares |
NORTHERN TRUST CORP | 0.44%1.97M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.44%1.96M shares |
VANGUARD FIDUCIARY TRUST CO | 0.37%1.63M shares |
CITADEL ADVISORS LLC | 0.36%1.6M shares |
Avicenna Life Sci Master GP LLC / Avicenna Life Sci Master Fund LP | ≈0.34%1.54M shares |
Ishara Investments LP | 0.28%1.27M shares |
MILLENNIUM MANAGEMENT LLC | 0.25%1.13M shares |
RENAISSANCE TECHNOLOGIES LLC | 0.25%1.13M shares |
Percentages use 446.87M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 25, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 2.0K | $1.49 | $3.0K | 1.91M |
| Feb 23, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 100.0K | $1.47 | $147.0K | 1.90M |
| Feb 20, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 100.0K | $1.48 | $148.0K | 1.80M |
| Feb 19, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 50.0K | $1.44 | $72.0K | 1.70M |
| Feb 18, 2026Form 4 | DEBBANE RAYMONDDirector | BuyCommon Stock | 133.7K | $1.32 | $176.5K | 1.65M |